Insmed reported $-79912000 in EBITDA for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Acelrx Pharmaceuticals ACRX:US $ -9.21M 0.35M
Alexion Pharmaceuticals ALXN:US $ 892.3M 186.4M
Alimera Sciences ALIM:US $ -1.79M 2.62M
Arena Pharmaceuticals ARNA:US $ -131.02M 3.32M
Biomarin Pharmaceutical BMRN:US $ 41.16M 14.24M
Cytokinetics CYTK:US $ -40.07M 4.14M
Dynavax Technologies DVAX:US $ 30.12M 40.65M
Flexion Therapeutics FLXN:US $ -22620000 8.72M
Gilead Sciences GILD:US $ 2816M 669M
Heron Therapeutics HRTX:US $ -51.38M 9.21M
Insmed INSM:US $ -79912000 10.78M
Mirati Therapeutics MRTX:US $ -132.13M 26M
Novartis NVS:US $ 4772M 423M
Regeneron Pharmaceuticals REGN:US $ 1180.1M 48.6M
Sarepta Therapeutics SRPT:US $ -132.94M 30.49M
Seattle Genetics SGEN:US $ -73.78M 33.35M
Ultragenyx Pharmaceutical RARE:US $ -79.66M 23.55M
Vertex Pharmaceuticals VRTX:US $ -5.12M 917.88M